Company overview. Fusion Orthopedics, LLC (operating publicly as Fusion Orthopedics USA, LLC, "Fusion") is a privately held medical-device company headquartered in Mesa, Arizona (4135 S. Power Rd.; newer filings list 6859 E. Rembrandt Ave.). The company says it was established in 2014; Tracxn reports a 2016 founding by President/co-founder Nathan Peterson, with CEO Adam Cundiff. Tracxn lists roughly 52 employees (as of April 2026) and revenue in the $1M–$5M band (as of March 2021), with about $810K in disclosed seed/debt funding. It is not publicly traded and no parent company is identified.
Products / operations. Fusion designs and sells foot-and-ankle orthopedic implants and instruments. Documented product lines include the Lapilock 4D Advanced Bunion Surgery system (bunion correction), the IntraLock Fixation System (Lapidus/intraosseous fixation), FuzeFix screw systems, the PolyLock Small Bone Plating System, HammerTech fixation, TalarLift STS, the FuseRight hammer-toe device (acquired from FootScientific in 2020), and — added in 2025 — Metalogix external fixation frames. Earlier acquisitions (Sgarlato Med, 2018; OrthoNoble, 2018) added additional foot/ankle and sports-medicine devices. Products have FDA 510(k) clearances (e.g., PolyLock, Fusion Silastic, Bolo Button).
Patent-litigation posture. Fusion is an operating company, not an NPE. In the tracked case data it appears once, as a defendant (0 plaintiff cases, 1 defendant case): Treace Medical Concepts, Inc. v. Fusion Orthopedics, LLC, filed March 29, 2022 in the U.S. District Court for the District of Arizona (2:22-cv-00490). The venue is Arizona, not a plaintiff-friendly patent docket like the Eastern District of Texas.
Notable cases / context. Treace Medical (NASDAQ: TMCI), maker of the Lapiplasty 3D Bunion Correction system, alleged patent, trademark, and copyright infringement and unfair trade practices over Fusion's Lapilock 4D system; Fusion counterclaimed for non-infringement, invalidity, and LAPIPLASTY trademark invalidity. The parties settled in March 2023 on confidential terms. Outside the tracked list, Fusion has also been publicly involved in a separate dispute with competitor Extremity Medical, which included PTAB inter partes review proceedings in which Fusion obtained invalidation of an Extremity Medical patent (2024).